The Statin Scare Is Causing Harm: When Health Advice Crosses the Line

Dr. Retzler finished another day of seeing patients recently and came away frustrated. It was not because patients were questioning a medication. She expects questions and wants patients to understand why a treatment is being considered before they agree to it. Her frustration was with how often the conversation about cardiovascular prevention now begins with fear that was created somewhere else.

She had again seen patients who were apprehensive about statins despite never having experienced a serious reaction to one, and in some cases despite never having taken one.

What they had heard instead came from podcasts, social media, wellness personalities, chiropractors, biohackers, supplement sellers and occasionally physicians who present statins as inherently dangerous, unnecessary, toxic or evidence of an outdated approach to cardiovascular disease.

At one point she said "These people are causing harm."

Her frustration comes from seeing the clinical reality that sits behind these conversations. She sees patients with atherosclerosis in the coronary and carotid arteries, elevated ApoB, high lipoprotein(a), diabetes, strong family histories of premature cardiovascular disease and combinations of risk that cannot be understood from a cholesterol number alone. She then has to help a patient reconcile that medical information with something they have heard online suggesting that lowering cholesterol is unnecessary, that statins cause dementia, that physicians have misunderstood atherosclerosis, or that supplements can provide equivalent protection.

For a physician whose work includes preventing cardiovascular disease before the heart attack or stroke occurs, this is more than a disagreement about treatment philosophy. It raises a question about what happens when confident health advice changes a patient's medical decisions without carrying any responsibility for what follows.

When Fear Enters the Exam Room

Patients have every reason to ask why a medication is being prescribed, what benefit they can reasonably expect from it, what adverse effects have been documented and whether other options are available. In cardiovascular prevention, additional testing may sometimes help clarify risk before a treatment decision is made. Depending on the clinical situation, that could include ApoB, lipoprotein(a), coronary artery calcium scoring or other forms of cardiovascular imaging used to identify or characterize atherosclerosis.

The difficulty arises when a patient enters that discussion having already been told that an entire category of medication is harmful. The physician is no longer simply explaining cardiovascular risk and treatment options. Part of the visit must now be spent working through claims the patient may have heard repeatedly from sources that appear authoritative, even though those sources have never reviewed the patient's history, laboratory results, imaging or overall cardiovascular risk.

Dr. Retzler's frustration is directed at that intrusion into the clinical relationship, not at the patient who has understandably become concerned. Repetition is persuasive, particularly when a message is emotionally compelling. A person who repeatedly hears that statins damage the brain, destroy muscles or exist largely because of pharmaceutical influence may understandably arrive at an appointment apprehensive about taking one.

The physician's responsibility is to take those concerns seriously while keeping the discussion anchored in evidence and in the medical circumstances of the individual patient.

Negative Messages Can Change Treatment Decisions

There is evidence that public messaging about statins can influence whether patients continue taking them. A large Danish population study followed 674,900 people who had started statin therapy and examined their exposure to positive and negative statin-related news stories. Exposure to negative coverage was associated with a greater likelihood of stopping treatment early. Early discontinuation was subsequently associated with higher rates of myocardial infarction and cardiovascular death.

The study was observational, so it cannot demonstrate that a particular news story caused an individual patient to stop a statin or that stopping the medication caused a particular cardiovascular event. That limitation matters when interpreting the findings. Evidence should not be exaggerated simply because it supports an argument we find persuasive.

What the study does show is that public discussion of medication can influence patient behavior on a very large scale.

Another Danish study examined adults age 75 and older who had been taking statins for at least five years. Discontinuation was associated with a higher rate of major cardiovascular events among patients receiving statins for both primary and secondary prevention. That study was also observational and should be interpreted accordingly, but it adds to the concern about casually encouraging patients to discontinue treatment without understanding why the medication was prescribed.

This is one reason physicians become uneasy when broad medical advice is delivered to large audiences without clinical context. One listener may have mild hyperlipidemia and little evidence of cardiovascular disease. Another may have established coronary atherosclerosis and several major risk factors. A message delivered to both people may sound equally certain even though their medical circumstances are very different.

Statin Symptoms and the Nocebo Effect

Muscle symptoms deserve particular attention because they are among the most common reasons patients stop statins and one of the most common concerns raised in the exam room.

The SAMSON trial studied patients who had previously stopped statins because of side effects. Participants alternated among periods taking atorvastatin, placebo tablets and no tablets without initially knowing whether they were receiving the statin or placebo. Symptoms increased during the months in which participants took atorvastatin, but they also increased to a remarkably similar degree during placebo months. There was no significant difference in symptom intensity between the statin and placebo periods.

The correct interpretation is not that the symptoms were imaginary. The patients experienced real symptoms that were clinically meaningful to them. The study demonstrated how expectations, background symptoms and the experience of taking medication can influence what a patient feels and subsequently attributes to a drug. After participants learned their individual results, approximately half had restarted statin treatment six months later.

A much larger individual-participant meta-analysis published in The Lancet, involving 123,940 people in 19 placebo-controlled statin trials, reached a compatible conclusion. During follow-up, muscle pain or weakness was reported by 27.1 percent of participants assigned to statins and 26.6 percent assigned to placebo.

The excess was concentrated primarily in the first year of treatment. During that period, statin therapy was associated with approximately 11 additional muscle-related events per 1,000 person-years. After the first year, the randomized evidence did not show a significant excess in muscle symptoms.

Put another way, the investigators estimated that more than 90 percent of muscle symptoms reported by people assigned to statins in randomized trials were not actually caused by the statin. That does not make the symptoms unimportant. It means that timing alone does not establish causation.

The StatinWISE trial reached a similar conclusion in patients who had previously reported muscle symptoms while taking statins. Muscle symptom scores were not significantly different during atorvastatin periods compared with placebo periods. After participants were shown their own blinded trial results, many subsequently resumed statin therapy.

This information should never be used to dismiss a patient who reports symptoms. It should improve the way those symptoms are evaluated. A clinician may need to consider other medical causes, medication interactions, the particular statin being used, the dose and dosing schedule, whether temporary discontinuation and rechallenge are appropriate, or whether another lipid-lowering therapy would be a better choice.

The Risks of Statin Therapy Should Be Discussed Honestly

Statins are prescription medications with recognized adverse effects. They should not be presented as biologically trivial simply because they have been studied extensively or because their cardiovascular benefits are well established in appropriate populations.

Muscle symptoms can occur. Rare serious muscle complications occur. Drug interactions can alter risk. Liver abnormalities require appropriate clinical evaluation. Large randomized analyses have also found a small increase in new-onset diabetes, with a somewhat greater proportional increase during higher-intensity statin therapy. Much of that excess diabetes risk appears among people who already have metabolic characteristics that place them near the diagnostic threshold for diabetes.

The 2026 Cholesterol Treatment Trialists' Collaboration analysis helps quantify some of these risks. Among people receiving low- or moderate-intensity statin therapy, new-onset diabetes occurred at an annual rate of approximately 1.3 percent compared with 1.2 percent with placebo, corresponding to a relative risk of 1.10. In trials comparing high-intensity with less intensive therapy, the relative increase was larger. Approximately 62 percent of the newly diagnosed diabetes cases occurred among participants whose baseline glycemia was already in the highest quarter of the study population.

Changes in liver tests were also confirmed, although the absolute increase was small. Elevated transaminases occurred at approximately 0.30 percent per year among participants taking statins compared with 0.22 percent per year among those taking placebo. When other abnormal liver-function tests were included, the estimated absolute annual excess was approximately 0.13 percent.

The same analysis found very small statistical increases in changes in urinary composition and edema. Edema occurred at annual rates of approximately 1.38 percent with statins and 1.31 percent with placebo. These findings deserve appropriate clinical attention, but their absolute magnitude is different from the impression created by a long list of possible adverse effects without information about frequency or causality.

Patients should know this before treatment begins. They should also understand why treatment is being considered in the first place.

A patient with established coronary atherosclerosis, substantial plaque burden, familial hypercholesterolemia, markedly elevated atherogenic lipoproteins, diabetes, chronic kidney disease or several cardiovascular risk factors faces a different balance of risk and benefit from a younger person with a modest LDL elevation and little evidence of atherosclerotic disease.

Neither a blanket assurance that statins are completely safe nor a blanket warning that they are dangerous is medically useful. The decision depends on the patient, the cardiovascular risk being treated, the expected benefit and the likelihood and severity of potential adverse effects.

What About Memory, Cognition, Depression and Sleep?

These concerns deserve specific attention because they are frequently raised by patients and are common themes in online discussions about statins.

Cholesterol is important in the nervous system, which can make claims about statins and brain function sound biologically plausible. The brain, however, regulates much of its cholesterol metabolism independently from circulating LDL cholesterol. A plausible mechanism should also not be confused with evidence that a clinically important adverse effect actually occurs.

The 2026 CTT analysis did not find robust evidence that statins increased cognitive impairment, depression or sleep disturbance in blinded randomized trials. A separate meta-analysis of randomized trials examining lipid-lowering therapy and neurocognitive outcomes likewise found no significant increase in neurocognitive events and no meaningful adverse effect across evaluated domains that included attention, processing speed, executive function, working memory and memory.

This does not mean that a patient reporting a cognitive change should be dismissed. New symptoms should be evaluated clinically. It does mean that claims that statins routinely cause dementia, memory loss, depression or sleep disorders are not supported by the strongest randomized evidence currently available.

Modern Cardiovascular Prevention Is More Sophisticated Than a Cholesterol Number

Some of the public debate about statins still seems to assume that contemporary cardiovascular medicine consists of finding an elevated LDL cholesterol level and automatically prescribing medication. That does not reflect modern preventive cardiology.

The 2026 American College of Cardiology and American Heart Association guideline on dyslipidemia incorporates cardiovascular risk assessment using the PREVENT equations, coronary artery calcium scoring when it can help clarify an uncertain treatment decision, lipoprotein(a), selective use of ApoB, LDL and non-HDL treatment goals, lifestyle intervention and several nonstatin therapies.

At HormoneSynergy®, the cardiovascular evaluation may extend beyond a conventional lipid panel when the clinical situation warrants it. ApoB can provide information about the number of circulating atherogenic particles. Lipoprotein(a) identifies an important inherited cardiovascular risk that is not apparent from a standard lipid panel. Coronary artery calcium scoring can identify calcified coronary atherosclerosis, while carotid imaging and more advanced coronary imaging may provide additional information about atherosclerotic disease in selected patients.

The purpose of this testing is not to find additional reasons to prescribe medication. It is to understand the patient's cardiovascular biology more accurately so that treatment can be proportional to risk.

That context is largely absent when someone tells a general audience that statins are unnecessary or that cholesterol should not be treated. The statement may reach someone with relatively little cardiovascular risk, but it may just as easily reach a person with significant subclinical or established atherosclerosis.

The Ethical Concern

Medical ethics places a longstanding obligation on physicians to avoid preventable harm. The wording of medical oaths has varied across history and institutions, and the familiar phrase "first, do no harm" does not appear verbatim in the classical Hippocratic Oath. The principle behind it, usually described as nonmaleficence, remains central to medical practice.

For a prescribing physician, that principle creates practical obligations. Before prescribing a medication, the clinician has to consider the indication, the patient's history, contraindications, potential adverse effects, alternatives, possible interactions, follow-up and what to do if treatment creates a problem. Responsibility does not end when the prescription is written.

Some forms of public health advice operate under a very different arrangement.

A person with a large audience may tell thousands of people that statins are toxic, that cholesterol does not contribute meaningfully to atherosclerotic disease, that physicians prescribe statins because they are influenced by pharmaceutical companies, or that supplements can provide comparable cardiovascular protection. That person usually does not know the medical history of the audience and may never know which listener has diabetes, severe hypercholesterolemia, significant atherosclerosis in the coronary or carotid arteries, familial hypercholesterolemia, a previous myocardial infarction or a markedly elevated lipoprotein(a).

Nor will that person usually be responsible for the clinical outcome if someone changes treatment because of what they heard.

That imbalance is what concerns Dr. Retzler. Advice can carry enough authority to influence a medical decision while remaining separated from the responsibility that normally accompanies medical treatment.

Scope of Practice Is Part of the Conversation

Some prominent anti-statin messages come from chiropractors, wellness coaches, biohackers, supplement marketers and other people whose professional work does not ordinarily include prescribing or managing lipid-lowering medication. That background is relevant because training and scope of practice influence both the problems a practitioner encounters and the treatments they are qualified to manage.

Credentials alone do not determine whether an argument is correct. Physicians can overstate evidence, misunderstand research and spread misinformation as readily as anyone else. A medical degree does not make every claim accurate, and the absence of a medical degree does not automatically make an observation wrong.

The more useful questions are whether the evidence is being represented accurately, whether the person is speaking within the limits of their expertise, whether important uncertainty is acknowledged and whether the consequences of the advice are being considered.

There is also an unavoidable limitation when a practitioner's therapeutic toolbox is narrow. If most available interventions consist of supplements, restrictive diets, wellness protocols or proprietary products, prescription therapy may repeatedly appear unnecessary simply because it lies outside that practitioner's usual scope. That does not diminish the importance of nonpharmaceutical treatment. Nutrition, exercise, smoking cessation, weight management and metabolic health are fundamental parts of cardiovascular prevention. It does mean that limitations in a practitioner's available treatments should not be mistaken for limitations in the medical evidence.

There Are Patients Who Should Not Be Taking a Statin

None of this supports indiscriminate statin prescribing.

There are patients whose cardiovascular risk is sufficiently low that pharmacologic lipid lowering may not be warranted. There are situations in which additional assessment is reasonable before treatment is started. Some patients develop adverse effects that justify changing the dose, changing the statin or stopping it. Others have genuine statin intolerance and may be candidates for ezetimibe, bempedoic acid, PCSK9-directed therapy or another approach depending on their underlying risk and treatment goals.

Lifestyle treatment remains foundational regardless of whether medication is used. Nutrition, physical activity, preservation of muscle mass, healthy body composition, blood pressure control, smoking avoidance, sleep, diabetes management and treatment of insulin resistance where appropriate all contribute to cardiovascular health.

These measures and medication should not be framed as competing ideologies. A patient with substantial atherosclerotic risk may benefit from intensive lifestyle treatment and pharmacologic lipid lowering at the same time. Another patient may reasonably begin with lifestyle intervention and continued risk assessment. The appropriate choice depends on the clinical situation rather than a philosophical preference for or against medication.

What a Responsible Statin Conversation Looks Like

A useful discussion begins with the patient's actual cardiovascular risk. Is there known atherosclerosis? What do LDL cholesterol, non-HDL cholesterol and ApoB show? Has lipoprotein(a) been measured? Is there diabetes, chronic kidney disease, hypertension, tobacco exposure or a strong family history of premature cardiovascular disease? Would imaging for coronary or carotid atherosclerosis materially change the assessment or the treatment decision?

If treatment is being considered, the discussion should include the expected benefit, the adverse effects the patient should know about and the plan if symptoms occur. For someone who has difficulty tolerating treatment, it may be reasonable to consider a different statin, a lower dose, an alternative schedule or a nonstatin therapy. These decisions are easier to make when the discussion remains centered on the individual patient rather than on broad claims about whether statins are inherently good or bad.

Cardiovascular disease is heterogeneous. People bring different genetics, metabolic health, plaque burden, medical histories and competing risks into the same discussion. A generalized statement made to an audience cannot account for those differences.

Why Dr. Retzler Feels So Strongly About This

Preventive medicine asks physicians and patients to make decisions about events that may still be years away. A patient can feel entirely well while coronary or carotid atherosclerosis progresses silently. Treating blood pressure, ApoB, diabetes or another cardiovascular risk factor can feel abstract because successful prevention often means that an event never occurs.

This makes preventive care particularly vulnerable to fear-based messaging. The possible adverse effect of a medication can be described vividly and immediately, while the myocardial infarction or stroke that prevention is intended to reduce may remain hypothetical for years.

Dr. Retzler has spent much of her career trying to identify cardiovascular risk early enough to do something about it. Her frustration comes from watching patients become afraid of treatment because someone who has never examined them, reviewed their imaging or evaluated their complete cardiovascular risk has spoken with greater certainty than the evidence justifies.

She does not want a patient pressured into taking a statin simply because a guideline or laboratory value suggests one. She wants the patient to understand why the medication is being considered and to have enough information to make an informed decision. She is equally concerned when a patient rejects potentially useful treatment because someone outside that clinical relationship has convinced them that taking the medication is itself evidence of poor medical judgment.

The physician's obligation in either situation is the same: present the evidence as accurately as possible, acknowledge uncertainty, explain the risks and benefits in the context of the individual patient, and respect the patient's decision.

When Health Advice Causes Harm

The internet has improved access to medical information in ways that have benefited patients and physicians alike. Patients can read research, learn about alternative treatments, hear different professional perspectives and arrive at appointments better prepared to participate in their own care. Medicine should not respond to that change by expecting patients to accept medical authority without question.

At the same time, access to information has made it possible for a persuasive speaker to influence the health decisions of an enormous audience without ever knowing the people receiving the advice. That influence carries responsibility, even when the information is being delivered as content rather than as medical care.

There are patients who should not take statins, patients who cannot tolerate them and patients whose cardiovascular risk does not justify treatment. There are also patients with substantial atherosclerotic disease or risk for whom declining effective lipid-lowering therapy may carry serious consequences. The difference between those patients cannot be determined from a podcast, a short video or a generalized statement about cholesterol.

Dr. Retzler's concern is ultimately less about defending statins than about protecting the quality of the medical decision. A patient deserves more than reassurance from one side and fear from the other. They deserve a careful assessment of their own cardiovascular risk, an honest discussion of what treatment can and cannot accomplish, and a clinician who remains responsible for their care after the conversation is over.

Anyone speaking publicly about medical treatment should approach that influence with similar care. If advice is strong enough to persuade someone to stop or refuse treatment, the possibility that the advice itself could cause harm deserves to be part of the conversation.

Frequently Asked Questions About Statin Side Effects

Do statins commonly cause muscle pain?

Statins can cause muscle symptoms in some patients, particularly during the first year of treatment, but randomized placebo-controlled trials show that most muscle symptoms reported by people taking statins are not actually caused by the medication. Symptoms should still be taken seriously and evaluated rather than dismissed.

Do statins cause dementia or memory loss?

Current randomized evidence does not show a reliable increase in cognitive impairment from statin therapy. Patients who experience new cognitive symptoms should discuss them with their clinician, but the available evidence does not support the broad claim that statins routinely cause dementia or memory loss.

Can statins increase diabetes risk?

Yes. Statins can modestly increase blood glucose and the likelihood of a new diabetes diagnosis, with a larger relative effect seen with higher-intensity therapy. Much of the excess risk occurs in people whose glucose levels are already near the diagnostic threshold for diabetes. The importance of that risk must be considered alongside the patient's cardiovascular risk and expected benefit from treatment.

Can statins affect the liver?

Statins can cause elevations in liver enzymes, although the absolute increase seen in randomized trials is small. An abnormal liver test does not automatically mean severe liver injury, but clinically significant abnormalities should be evaluated appropriately.

Should someone stop a statin because they develop symptoms?

Not automatically. New symptoms deserve evaluation because they may be caused by the statin, another medication, an interaction, another medical condition or background symptoms unrelated to treatment. Depending on the situation, a clinician may consider a temporary interruption, rechallenge, different dose, different statin or a nonstatin lipid-lowering therapy.

Are statins appropriate for everyone with high cholesterol?

No. Treatment decisions should reflect overall cardiovascular risk rather than a cholesterol value in isolation. Factors may include existing atherosclerosis, LDL cholesterol, non-HDL cholesterol, ApoB, lipoprotein(a), diabetes, kidney disease, blood pressure, smoking exposure, family history and, when appropriate, cardiovascular imaging.

References & Further Reading

• American Heart Association: 2026 Guideline on the Management of Dyslipidemia
• Cholesterol Treatment Trialists' Collaboration. Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials. The Lancet. 2026.
• Nielsen SF, Nordestgaard BG. Negative statin-related news stories, statin discontinuation and cardiovascular outcomes. European Heart Journal.
• Howard JP, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. SAMSON trial.
• Cholesterol Treatment Trialists' Collaboration. Effect of statin therapy on muscle symptoms. The Lancet.
• Cholesterol Treatment Trialists' Collaboration. Statin therapy, new-onset diabetes and worsening glycaemia. Lancet Diabetes & Endocrinology.
• Thompson W, et al. Statin Discontinuation and Cardiovascular Events Among Older People in Denmark. JAMA Network Open.

Related HormoneSynergy® Articles

Understanding Statin Phobia: Who's Pushing It and Why It Can Be Dangerous

Statins, Fear Marketing and Anti-Medicine Influencers

This article is provided for educational purposes and is not individual medical advice. Decisions about lipid-lowering therapy should be made with a qualified clinician who can evaluate personal cardiovascular risk, medical history, medications, laboratory findings and, when appropriate, cardiovascular imaging.